Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Philippe Halfon_2023
Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma
Shots: Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent) He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone The interview gives an…
June 15, 2023
VIEWPOINTS_Rui Avelar_2023
Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau
Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023
VIEWPOINTS_Eric Halioua_2023
Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01
Shots: Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate The interview shows PDC*line’s vision…
June 1, 2023
VIEWPOINTS_Monica Mann_2023
Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research
Shots: Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meeting The highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiatives The interview shows how Biogen develops, and delivers…
May 31, 2023
VIEWPOINTS_Gregory Bell_2023
Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology
Shots: Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease He also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023
VIEWPOINTS_David Pendlebury_2023
David Pendlebury, Head of Research Analysis, Institute for Scientific Information Shares Insights from its Annual Highly Cited Researchers List
Shots: David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regions He also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…
May 29, 2023
VIEWPOINTS_Dr. Samiah Al-Zaidy_2023
Dr. Samiah Al-Zaidy, VP of Clinical Development at Passage Bio Shares Insights on Additional Interim Data from the Imagine-1 Study for GM1 Gangliosidosis
Shots: Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023 She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal disease The interview showcases Passage Bio’s mission to…
May 22, 2023
Load more